Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 4
1994 5
1995 4
1996 4
1997 5
1998 14
1999 16
2000 15
2001 12
2002 24
2003 16
2004 13
2005 22
2006 39
2007 34
2008 28
2009 29
2010 28
2011 41
2012 56
2013 48
2014 59
2015 51
2016 37
2017 35
2018 40
2019 29
2020 42
2021 58
2022 24
Text availability
Article attribute
Article type
Publication date

Search Results

740 results
Results by year
Filters applied: . Clear all
Page 1
Case Report.
Almacan B, Ozdemir N, Gürkan H, Gul S, Guldiken S, Hekimsoy Z. Almacan B, et al. Among authors: ozdemir n. Acta Endocrinol (Buchar). 2021 Jul-Sep;17(3):388-392. doi: 10.4183/aeb.2021.388. Acta Endocrinol (Buchar). 2021. PMID: 35344314 Free PMC article.
(E)-4-{[(Morpholin-4-yl)imino]-meth-yl}benzo-nitrile.
Atioğlu Z, Akkurt M, Jarrahpour A, Heiran R, Ozdemir N. Atioğlu Z, et al. Among authors: ozdemir n. Acta Crystallogr Sect E Struct Rep Online. 2014 Jun 21;70(Pt 7):o799. doi: 10.1107/S1600536814014020. eCollection 2014 Jul 1. Acta Crystallogr Sect E Struct Rep Online. 2014. PMID: 25161580 Free PMC article.
3-(2,4-Di-chloro-phen-oxy)-1-(4-meth-oxy-benz-yl)-4-(4-nitro-phen-yl)azetidin-2-one.
Atioğlu Z, Akkurt M, Jarrahpour A, Heiran R, Ozdemir N. Atioğlu Z, et al. Among authors: ozdemir n. Acta Crystallogr Sect E Struct Rep Online. 2014 Jul 2;70(Pt 8):o835-6. doi: 10.1107/S1600536814015013. eCollection 2014 Aug 1. Acta Crystallogr Sect E Struct Rep Online. 2014. PMID: 25249889 Free PMC article.
1-(Morpholin-4-yl)-4-(2-nitro-phen-yl)spiro-[azetidine-3,9'-xanthen]-2-one.
Atioğlu Z, Akkurt M, Jarrahpour A, Heiran R, Ozdemir N. Atioğlu Z, et al. Among authors: ozdemir n. Acta Crystallogr Sect E Struct Rep Online. 2014 Jun 14;70(Pt 7):o772-3. doi: 10.1107/S1600536814013464. eCollection 2014 Jul 1. Acta Crystallogr Sect E Struct Rep Online. 2014. PMID: 25161561 Free PMC article.
1,1'-(Piperazine-1,4-di-yl)dipropan-2-ol.
Türkyılmaz M, Baran Y, Ozdemir N. Türkyılmaz M, et al. Among authors: ozdemir n. Acta Crystallogr Sect E Struct Rep Online. 2011 Jul 1;67(Pt 7):o1758. doi: 10.1107/S1600536811023397. Epub 2011 Jun 22. Acta Crystallogr Sect E Struct Rep Online. 2011. PMID: 21837140 Free PMC article.
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.
Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Giangrande P, Peerlinck K, Celkan T, Ozdemir N, Bidlingmaier C, Ingerslev J, Giansily-Blaizot M, Schved JF, Gilmore R, Gadisseur A, Benedik-Dolničar M, Kitanovski L, Mikovic D, Musallam KM, Rosendaal FR; European Network of Rare Bleeding Disorders Group. Peyvandi F, et al. Among authors: ozdemir n. J Thromb Haemost. 2012 Apr;10(4):615-21. doi: 10.1111/j.1538-7836.2012.04653.x. J Thromb Haemost. 2012. PMID: 22321862 Free article.
Thirty-day mortality rates after immunotherapy initiation.
Sütcüoğlu O, İlhan A, Tacar SY, Güven DC, Uçar G, Karadurmuş N, Yıldız F, Eraslan E, Uncu D, Tural D, Üner A, Günel N, Özdemir N, Kılıçkap S, Öksüzoğlu ÖB, Özet A, Yazıcı O. Sütcüoğlu O, et al. Among authors: ozdemir n. Immunotherapy. 2021 Dec;13(17):1419-1426. doi: 10.2217/imt-2021-0082. Epub 2021 Oct 22. Immunotherapy. 2021. PMID: 34676791
A Rare Lymphoproliferative Disease: Castleman Disease.
Gündüz E, Özdemir N, Bakanay ŞM, Karakuş S. Gündüz E, et al. Among authors: ozdemir n. Turk J Haematol. 2021 Dec 7;38(4):314-320. doi: 10.4274/tjh.galenos.2021.2021.0440. Epub 2021 Nov 1. Turk J Haematol. 2021. PMID: 34719151 Free PMC article.
740 results